Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib re-challenge in advanced EGFR-mutated NSCLC
NCT02025218Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoint: Disease Control Rate. Started Jan 2014; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02025218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025218.